HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include
"cT4aNxM0, P0 or cTxNxM1, P1" patients with gastric or esophagogastric junction
adenocarcinoma, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC
combined with AS in the perioperative period. Patients enrolled will be divided into three
groups. Among them, group A is the patients with locally resectable GC; group B is patients
with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis
stage P1c. The primary purpose is to evaluate the 3-year overall survival rate.